| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| « Feb | Apr » | |||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
Alfacell Corp., the New Jersey pharmaceutical company, got enough patients to go ahead with phase IIIb testing on Onconase, (ranpirnase). Another step in the long process toward getting approval for that drug, which is promising in mesothelioma treatment. The drug companies sometimes target mesothelioma in their development process even though it is a rare form [...]
Impact Analysis blog talks about the integrity of B Readers as expert witnesses in occupational health court cases. NIOSH B Reader approval is granted to physicians who demonstrate proficiency in the classification of chest radiographs for the pneumoconioses using the International Labour Office (ILO) Classification System. Mesothelioma Aid’s write-up on B-readers is here. This is [...]
This is a pretty common mistake in the popular press – thinking mesothelioma is a form of lung cancer. In mesothelioma, the tumor is on the mesothelium, which is the lining of the pleural cavity. In lung cancer, the tumor is in the lung tissue. In this case, the story was on Dana Reeve, the [...]